Experts pinpoint problems with the FDA's tobacco program

POLITICO's Pulse Check

The FDA’s tobacco regulatory decision-making process is so slow and opaque that it’s ineffective, say legal, industry and public health experts appearing before an outside panel conducting a commissioner-mandated review of the program. Katherine Ellen Foley talks with Ben Leonard. Plus, Greer Donley, a professor specializing in reproductive health care at the University of Pittsburgh Law School, breaks down what the FDA’s stance on doctors prescribing abortion pills to people who aren’t yet pregnant means in practice.